

# Index

## A

- AAV. *See* Adeno-associated virus
- ABCA4*
  - age-related macular degeneration susceptibility studies, 161–162
  - allele frequency, 48
  - gene therapy
    - adeno-associated virus vectors, 291–293
    - lentivirus vectors, 293–294
    - overview, 289–290, 429
    - plasmid vectors, 290–291
    - prospects, 294
  - genetic modifiers, 61–62
  - induced pluripotent stem cell modeling of diseases, 92–93
  - Stargardt disease mutations, 9, 42, 289
- Abetalipoproteinemia. *See* Bassen–Kornzweig syndrome
- Achromatopsia
  - clinical features, 11
  - gene mutations, 11
  - neuroprotection, 15
- Adeno-associated virus (AAV), gene therapy vectors
  - ABCA4* delivery, 291
  - angiostatin delivery, 314–315
  - CHM* delivery, 281–285
  - MYO7A* delivery
    - dual vectors, 304–305
    - single vectors, 303–304
  - overview, 12–14
  - PRPH2* delivery, 352–354
  - RHO* delivery, 389–391
  - RPE65* delivery, 260, 263–265, 282, 427–430
  - RPGR* delivery, 276–382
  - RS1* delivery, 337–341, 343
  - sFLT delivery, 311–313
- Adenovirus, gene therapy vector for PEDF delivery, 313–314
- Advanced glycation end products (AGEs), drusen, 147–148
- Aflibercept, age-related macular degeneration management, 121
- Age-related macular degeneration (AMD)
  - classification, 109, 169, 182
  - clinical application of genetics studies
    - classification and subtyping of disease, 186–187
    - drug development, 187–188
    - linkage structure, 186–188
    - nature of variation, 185
    - overview, 181–182
    - pathogenesis and pathophysiology, 184
    - prospects, 188–189
    - risk prediction, 186
    - techniques for study, 182–184
    - variant frequency and effect magnitude, 184–185
- clinical features
  - early and intermediate disease, 111
  - geographic atrophy, 112–114
  - neovascular disease, 113–116
  - normal aging, 110–111
  - overview, 109–110, 128, 182
  - polyploid choroidal vasculopathy, 116–117
  - reticular pseudodrusen, 112
  - retinal angiomatous proliferation, 117
- drusen. *See* Drusen
- gene expression studies
  - DNA microarrays, 174–176
  - factors affecting gene expression
    - epigenetics, 173–174
    - genetic variation, 172–173
    - splice variants, 173
  - resources, 170
  - RNA-Seq, 174–176
  - sample considerations, 171–172
- gene therapy for neovascular disease
  - angiostatin, 314–315
  - endostatin, 314–315
  - pigment epithelium-derived factor, 313–314
  - prospects, 315
  - vascular endothelial growth factor inhibitors, 310–312
- genome-wide association studies in susceptibility
  - ARMS2*, 129, 134
  - BF*, 132
  - C2*, 132, 134
  - C3*, 133, 135
  - C5*, 133
  - C9*, 135
  - CFB*, 134
  - CFD*, 133
  - CFG*, 133
  - CFH*, 129–134
  - CFHR* genes, 132

## Index

- Age-related macular degeneration (AMD) (*Continued*)  
CFI, 133, 135  
CFP, 133  
genetic risk scores, 136–137  
HTRA1, 129, 134  
meta-analysis of studies, 134–135  
PLEKHA1, 129  
prospects, 135–136  
highly penetrant alleles  
ARMS2, 155–156  
CFH, 155–156, 159–161  
HTRA1, 155–156  
overview, 155–157  
rare variants  
ABCA4, 161–162  
C3, 158–159  
C9, 159  
candidate gene analysis, 157–158  
CFI, 161  
clinical subtypes, 164  
exome chip analysis, 158  
exome sequencing, 158  
FBLN5, 162  
HMCN1, 163  
linkage analysis, 157  
predictive testing, 163–164  
prospects for study, 164–165  
whole genome sequencing, 158  
induced pluripotent stem cell modeling, 94–95  
risk factors, 110, 128–129, 170  
RNA-Seq studies, 83–84  
treatment  
neovascular disease  
aflibercept, 121  
bevacizumab, 121  
combination therapy, 121  
macular surgery, 119–120  
pegaptanib, 120  
photocoagulation, 119  
photodynamic therapy, 120–121  
ranibizumab, 120–121  
nonneovascular disease, 118–119  
AGEs. *See* Advanced glycation end products  
AHII, genetic modifiers, 62, 64  
AIP1L1, Leber congenital amaurosis variants, 44  
ALMS1  
Alström disease mutations, 101  
inherited retinal degeneration, 46  
Alström disease  
clinical features, 101–102  
hearing loss, 100  
AMD. *See* Age-related macular degeneration  
Amyloid- $\beta$ , drusen formation, 149  
Angiostatin, gene therapy for age-related macular degeneration, 314–315  
ARMS2  
age-related macular degeneration susceptibility studies, 129, 134, 156  
induced pluripotent stem cell modeling of mutation, 95  
**B**  
Bardet–Biedl syndrome (BBS)  
clinical features, 103  
gene mutations, 46  
genetic modifiers, 59, 62, 65  
retinitis pigmentosa, 6  
Basal laminar deposits (BLamD), age-related macular degeneration, 111  
Bassen–Kornzweig syndrome (BKS), clinical features, 103  
BBS. *See* Bardet–Biedl syndrome  
BCD. *See* Bietti’s crystalline retinal dystrophy  
BDNF. *See* Brain-derived neurotrophic factor  
BEST1, induced pluripotent stem cell modeling of mutation, 94  
 $\beta$ -Carotene, age-related macular degeneration management, 118  
Bevacizumab, age-related macular degeneration management, 121  
BF, age-related macular degeneration susceptibility studies, 132  
Bietti’s crystalline retinal dystrophy (BCD), clinical features, 104  
Bimatoprost, glaucoma management, 201  
BKS. *See* Bassen–Kornzweig syndrome  
BLamD. *See* Basal laminar deposits  
Brain-derived neurotrophic factor (BDNF), neuroprotection, 15  
BrainPort, 18  
**C**  
CABP4, congenital stationary night blindness mutations, 10  
CACD. *See* Central areolar choroidal dystrophy  
CACNA1F, congenital stationary night blindness mutations, 10  
CACNA2D4, congenital stationary night blindness mutations, 10  
Candidate gene analysis  
age-related macular degeneration susceptibility studies, 157–158  
genetic modifier identification, 62  
CAV1, glaucoma mutations, 211–212  
CAV2, glaucoma mutations, 211–212  
CCDC28B, genetic modifiers, 57–58, 62, 65  
CCT. *See* Central corneal thickness  
CDKN2BAS  
glaucoma mutations, 211–213, 215  
therapeutic targeting, 255

- Central areolar choroidal dystrophy (CACD),
  - clinical features, 104
- Central corneal thickness (CCT), glaucoma, 195, 213
- CEP290*
  - genetic modifiers, 56, 64
  - inherited retinal degeneration, 44, 46
  - mouse model of Leber congenital amaurosis, 416
  - mutation effects, 105–106
  - pathogenicity of mutations, 50
  - retinitis pigmentosa mutations, 6–7
- CFB*, age-related macular degeneration
  - susceptibility studies, 134
- CFD*, age-related macular degeneration
  - susceptibility studies, 133
- CFG*, age-related macular degeneration
  - susceptibility studies, 133
- CFH*
  - age-related macular degeneration susceptibility
    - studies, 129–134, 155–156, 159–161, 182–183
  - drusen formation, 149–150
  - genetic modifiers, 59
  - induced pluripotent stem cell modeling
    - of mutation, 95
  - ligand lipoxidation in drusen, 148
- CFHR* genes, age-related macular degeneration
  - susceptibility studies, 132
- CFI*, age-related macular degeneration susceptibility
  - studies, 133, 135, 161
- CFR*, age-related macular degeneration susceptibility
  - studies, 133
- Channel rhodopsin-2 (ChR2), optogenetics, 16–17
- CHM*
  - choroideremia mutations, 10, 42
  - gene therapy
    - clinical trials, 284–285
    - overview, 13, 275–277
    - prospects, 285
    - vector
      - design, 280–283
      - preclinical testing of AAV2 vector, 283–284
  - protein. *See* REP1
- Choroidal neovascularization (CNV), age-related
  - macular degeneration, 113–116
- Choroideremia
  - CHM* gene therapy
    - clinical trials, 284–285
    - overview, 13, 275–277
    - prospects, 285
    - vector
      - design, 280–283
      - preclinical testing of AAV2 vector, 283–284
  - clinical features, 9–10
  - epidemiology, 277
  - gene mutations, 275–278
  - history of study, 277
  - molecular diagnosis, 277–278
  - REP1
    - animal mutant studies, 279–280
    - expression and function, 278–279
- ChR2. *See* Channel rhodopsin-2
- Ciliary neurotrophic factor (CNTF)
  - gene therapy, 356
  - neuroprotection, 15, 255–256, 376
- 9-*cis*-Retinal, Retinal degeneration management
- CLN1*, neuronal ceroid lipofuscinosis mutation,
  - 103–104
- CLN3*
  - mutation effects, 106
  - neuronal ceroid lipofuscinosis mutation, 104
- CLRN1*, Usher syndrome mutations, 46
- CNGA1*, retinitis pigmentosa mutations, 5
- CNGA3*, achromatopsia mutations, 11, 46
- CNGB3*
  - achromatopsia mutations, 11
  - gene therapy, 13–14
- CNTF. *See* Ciliary neurotrophic factor
- CNV. *See* Choroidal neovascularization; Copy number variation
- COL11A1*, glaucoma mutations, 213
- COL15A1*, genetic testing, 252
- COL18A1*, genetic testing, 252
- Color blindness
  - developmental neural plasticity, 401
  - gene therapy prospects, 410–411
  - mouse trichromacy with M opsin knock-in,
    - 408–409
  - squirrel monkey trichromacy
    - biological basis of trichromacy in primates,
      - 406–408
    - evolutionary mechanism of shift from dichromacy, 405, 409
  - gene therapy
    - delivery, 409–410
    - L opsin, 402–405
  - neural networks in newly trichromatic primates, 406
  - neural plasticity, 405–406
  - photopigments, 402
- Complement
  - activation pathways, 127
  - age-related macular degeneration
    - genome-wide association studies in susceptibility
      - ARMS2*, 129, 134
      - BF*, 132
      - C2*, 132, 134
      - C3*, 133, 135
      - C5*, 133
      - C9*, 135
      - CFB*, 134
      - CFD*, 133

## Index

### Complement (*Continued*)

- CFG, 133
- CFH, 129–134
- CFHR genes, 132
- CFI, 133, 135
- CFP, 133
- genetic risk scores, 136–137
- HTRA1, 129, 134
- meta-analysis of studies, 134–135
- PLEKHA1, 129
- prospects, 135–136
- highly penetrant alleles
  - C3, 158–159
  - C9, 159
  - CFH, 155–156, 159–161
  - CFI, 161
- glaucoma cascade, 238–239, 243–245
- Cone–rod degenerations/dystrophies (CORDs),
  - overview, 7
- Congenital stationary night blindness (CSNB)
  - clinical features, 10
  - gene mutations, 10
- Copy number variation (CNV), inherited retinal degeneration, 45–46
- CORDs. *See* Cone–rod degenerations/dystrophies
- CRB1, Leber congenital amaurosis variants, 44
- CRISPR/Cas system, genome editing, 420–421
- CRX
  - Leber congenital amaurosis mutations, 7
  - retinitis pigmentosa mutations, 5
- CSNB. *See* Congenital stationary night blindness
- CYP11B
  - genetic testing, 250–252
  - glaucoma expression, 222
  - glaucoma mutations, 208, 215
  - therapeutic targeting, 255

## D

- DHA. *See* Docosahexaenoic acid
- DNA microarrays, age-related macular degeneration gene expression studies, 174–176
- Docosahexaenoic acid (DHA), retinal degeneration management, 11
- Drusen
  - clinical features, 112, 141
  - formation, 142, 149
  - proteomics studies in age-related macular degeneration
    - oxidative protein modifications, 146–149
    - prospects, 149–150
    - qualitative studies, 142–143
    - quantitative studies
      - Bruch's membrane/choroid, 143–145
      - mouse studies, 144, 146

## E

- Eculizimab, age-related macular degeneration management, 119
- EFEMP1. *See* Extracellular matrix protein 1
- EIAV. *See* Equine infectious anemia virus
- Electroretinogram (ERG)
  - achromatopsia findings, 11
  - choroideremia findings, 10
  - congenital stationary night blindness findings, 10
  - Leber congenital amaurosis findings, 7
  - retinitis pigmentosa findings, 2–3
  - Stargardt disease findings, 8
  - X-linked retinoschisis findings, 8, 334–335
- Embryonic stem cell (ESC)
  - cell therapy, 17–18
  - gene therapy, 416
- Endostatin, gene therapy for age-related macular degeneration, 314–315
- ENDRA, genetic modifiers, 58
- ENDRB, genetic modifiers, 60
- Equine infectious anemia virus (EIAV), gene therapy vectors
  - endostatin delivery, 315
  - MYO7A delivery, 302–303
  - overview, 14
- ERAP1, genetic modifiers, 70
- ERG. *See* Electroretinogram
- ESC. *See* Embryonic stem cell
- EST. *See* Expressed sequence tags
- Estrogen, metabolism and glaucoma, 215
- Exome chip analysis, age-related macular degeneration susceptibility studies, 158
- Exome sequencing
  - age-related macular degeneration susceptibility studies, 158
  - next generation sequencing, 44–45
- Expressed sequence tags (EST), overview, 77
- Extracellular matrix protein 1 (EFEMP1), 144, 146, 149

## F

- FAM161A, variant prioritization, 49
- Fanconi anemia, gene therapy, 418
- FBLN5, age-related macular degeneration susceptibility studies, 162
- FCD. *See* Fuchs corneal dystrophy
- FECH, genetic modifiers, 58
- FGF. *See* Fibroblast growth factor
- Fibroblast growth factor (FGF), FGF-2
  - neuroprotection, 15
- Fluorescein angiography, choroidal neovascularization, 114
- FOXC1
  - genetic testing, 250–252, 254
  - glaucoma mutations, 209
- FTO, genetic modifiers, 58

- Fuchs corneal dystrophy (FCD), genetic modifiers, 60
  - Fundus autofluorescence
    - retinitis pigmentosa findings, 2–3
    - Stargardt disease findings, 8–9
  - G**
  - Gene therapy. *See also specific diseases and genes*
    - economic considerations, 432–433
    - efficacy improvement, 429–431
    - indications, 12–14
    - limitations, 431–432
    - outcome measures, 432
    - prospects, 433
    - success stories, 427–429
    - vectors, 12–13
  - Genetic modifiers
    - cloning strategies
      - candidate gene approach, 62
      - candidate locus association studies, 60, 62
      - linkage analysis, 60
      - mouse strain studies, 63–64
      - overview, 60–61
      - system-based candidates, 62
      - transcriptome analysis, 62–63
      - whole-exome data in toto, 63
    - identification challenges
      - nongenetic factors, 59–60
      - study availability, 59
    - overview, 55–56
    - properties
      - allelic heterogeneity, 56
      - locus sharing with disease driver, 58
      - multiple interactions, 56–58
      - variant frequency in general population, 58–59
    - prospects for study, 70–71
    - retinal degeneration studies
      - humans, 64–65, 67–68
      - mice, 66, 68–70
  - Genome editing, induced pluripotent stem cells, 419–421
  - Geographic atrophy, age-related macular degeneration, 112–114
  - GFAP. *See* Glial fibrillary acidic protein
  - Glaucoma
    - etiology, 192–193
    - gene expression studies
      - anterior eye, 222
      - ganglion cell central projecting targets, 228
      - optic nerve, 225–228
      - overview, 221–222
      - prospects for study, 228–229
      - retina, 222–225
    - genetics
      - adult-onset glaucoma
      - normal-tension glaucoma, 212
      - overview, 211–212
      - primary open-angle glaucoma, 213
      - pseudoexfoliation syndrome, 212–213
      - qualitative ocular traits as risk factors, 213
    - complex interactions, 213–214
    - early-onset disease
      - congenital glaucoma, 208–209
      - developmental glaucoma, 209
      - juvenile-onset primary open-angle glaucoma, 209–211
      - normal-tension glaucoma, 211
      - overview, 207–208
    - estrogen metabolism, 215
    - extracellular matrix metabolism, 215
    - gene discovery rationale, 207
    - prospects for study, 215
    - transforming growth factor- $\beta$  signaling, 215
    - tumor necrosis factor- $\alpha$  signaling, 215
  - genetic testing
    - adult-onset glaucoma, 262
    - approaches, 254
    - early-onset glaucoma
      - gene mutations, 250
      - informed genetic counseling, 250–251
      - presymptomatic risk assessment, 251
      - surveillance and treatment plans, 251–252
    - limitations, 254
    - overview, 250
    - recommendations, 252
  - history taking, 193–194
  - natural history, 191–192
  - neuroinflammation and retinal ganglion cell loss
    - astrocyte and microglia activation, 239–240
    - beneficial and damaging effects, 239
    - complement cascade, 238–239, 243–245
    - immune response, 236
    - inflammation signaling, 240–242
    - leukocyte transendothelial migration, 238, 242–243
    - overview, 235–236
    - triggers, 236–238, 240
  - novel therapy identification, 254–256
  - ophthalmic examination, 194–198
  - treatment
    - clinical trials, 203–204
    - laser therapy, 202
    - medical therapy, 200–202
    - overview, 197, 200
    - surgery, 202, 204
  - types, 192
- Glial fibrillary acidic protein (GFAP), glaucoma expression, 225, 228
- Glutathione S-transferase (GST), expression in age-related macular degeneration, 174
- GNAT2, achromatopsia mutations, 11
- Gonioscopy, glaucoma, 194–195

## Index

- GPR179*, congenital stationary night blindness mutations, 10
- GRM6*, congenital stationary night blindness mutations, 10
- GST. *See* Glutathione S-transferase
- Guanylate cyclase. *See* *GUCY2D*
- GUCY2D*  
gene therapy prospects, 327–328  
Leber congenital amaurosis mutations  
animal models  
GC1/GC2 double knockout mouse, 325–327  
GUCY1\*B chicken, 321–323  
knockout mouse, 323–325  
guanylate cyclase functions, 319–320  
patient characterization, 320–321
- GUCY2D*, Leber congenital amaurosis variants, 44
- Gyrate atrophy, *OAT* mutation, 42, 104
- ### H
- Hirschsprung disease, genetic modifiers, 58
- HIV. *See* Human immunodeficiency virus
- HK1*, retinitis pigmentosa mutations, 35, 106
- HMCN1*  
age-related macular degeneration susceptibility studies, 163  
variant prioritization, 49
- HTRA1*  
age-related macular degeneration susceptibility studies, 129, 134, 155–156  
expression in age-related macular degeneration, 172  
induced pluripotent stem cell modeling of mutation, 95
- Human immunodeficiency virus (HIV), gene therapy vector for *MYO7A* delivery, 302
- ### I
- IBD. *See* Identity by descent
- Identity by descent (IBD), mapping, 45
- IFRD1*, genetic modifiers, 58
- IMPDH1*  
Leber congenital amaurosis mutations, 7  
retinitis pigmentosa mutations, 34–35
- Indocyanine green angiopathy, polyploid choroidal vasculopathy, 117
- Induced pluripotent stem cell (iPSC)  
cell therapy, 17–18, 91  
differentiation, 92  
gene therapy  
Fanconi anemia, 418  
genome editing, 419–421  
promoters, 419  
prospects, 421–422  
timing, 418  
vectors, 417–418  
generation, 417  
photoreceptor cell differentiation, 416–417  
retinal disease modeling  
*ABCA4* diseases, 92–93  
age-related macular degeneration, 94–95  
*BEST1* mutation, 94  
*MAK* mutation, 93  
overview, 92  
prospects, 95–96  
*USH2A* mutation, 93–94  
RNA-Seq studies, 83
- iPSC. *See* Induced pluripotent stem cell
- IQCB1*  
genetic modifiers, 65  
inherited retinal degeneration, 46
- IRX3*, genetic modifiers, 58
- ### J
- Joubert syndrome  
gene mutations, 46  
retinitis pigmentosa, 6–7
- ### L
- Latanoprost, glaucoma management, 201
- LCA. *See* Leber congenital amaurosis
- Leber congenital amaurosis (LCA)  
animal models of *RPGRI1* mutation, 365–367  
clinical features, 7–8, 363  
epidemiology, 7  
gene therapy  
genes. *See* *RPE65*; *RPGRI1*  
overview, 12–13  
*GUCY2D* mutations  
animal models  
GC1/GC2 double knockout mouse, 325–327  
GUCY1\*B chicken, 321–323  
knockout mouse, 323–325  
gene therapy prospects, 327–328  
guanylate cyclase functions, 319–320  
patient characterization, 320–321
- Leber's hereditary optic neuropathy. *See* Primary optic neuropathy
- Lentivirus gene therapy vectors. *See also specific viruses*  
*ABCA4* delivery, 293–294  
*MYO7A* delivery, 302–303
- Leukocyte transendothelial migration, glaucoma, 238, 242–243
- Linkage analysis  
age-related macular degeneration susceptibility studies, 157  
genetic modifier identification, 60  
inherited retinal degeneration, 45–46
- LMX1B*, glaucoma mutations, 209

- L opsin, gene therapy in dichromatic primates, 402–405
- LOXL1*  
genetic testing, 252  
glaucoma mutations, 213
- LRIT3*, congenital stationary night blindness mutations, 10
- LTBP2*  
genetic testing, 250–252  
glaucoma mutations, 208–209, 215
- Lutein  
age-related macular degeneration management, 118  
retinal degeneration management, 11
- M**
- MAK*  
induced pluripotent stem cell modeling of mutation, 93  
variant prioritization, 49
- MBL2*, genetic modifiers, 58
- MELAS*, pigmentary retinopathy, 102
- MERTK*, gene therapy, 13
- MFSD8*, mutation effects, 106
- Mitochondrial disease, pigmentary retinopathy, 102
- Mtap1a*, genetic modifiers, 66
- MTTP*, Bassen–Kornzweig syndrome mutation, 103
- MVK*, retinitis pigmentosa mutations, 46
- MYO7A*  
gene therapy  
adeno-associated virus vectors  
dual vectors, 304–305  
single vectors, 303–304  
equine infectious anemia virus vectors, 302–303  
human immunodeficiency virus vectors, 302  
prospects, 306, 429  
splice variants, 305–306  
inherited retinal degeneration, 46  
mouse mutants, 299–302
- MYOC*  
genetic testing, 250–252  
glaucoma mutations, 210, 215  
therapeutic targeting, 255
- N**
- Neuronal ceroid lipofuscinosis, clinical features and gene mutations, 103–104
- Next generation sequencing (NGS). *See also* RNA-Seq  
autosomal dominant retinitis pigmentosa genetic testing, 28, 30–31, 36  
clinical applications in ophthalmology, 78–79  
exome sequencing, 44–45  
overview, 78  
targeted sequencing, 44
- NGS. *See* Next generation sequencing
- Nilvadipine, retinal degeneration management, 16
- NOD-like receptors, glaucoma  
neuroinflammation role, 237
- Normal-tension glaucoma. *See* Glaucoma
- NPHP1*, genetic modifiers, 62
- NR2E3*, retinitis pigmentosa mutations, 5
- NRL*, retinitis pigmentosa mutations, 5
- NYX*, congenital stationary night blindness mutations, 10
- O**
- OAT*, gyrate atrophy mutation, 42, 104
- OCT. *See* Optical coherence tomography
- OFD1*, Joubert syndrome mutations, 46
- OPA1*, genetic testing, 252–254
- OPA3*, genetic testing, 252–254
- Optic nerve disorders. *See* Glaucoma; Primary optic neuropathy
- Optical coherence tomography (OCT)  
achromatopsia findings, 11  
choroidal neovascularization, 115–116  
congenital stationary night blindness findings, 10  
gene therapy studies, 430  
glaucoma, 197–198  
patient selection for retinal degeneration treatment, 18  
reticular pseudodrusen, 112  
retinitis pigmentosa findings, 2–3  
Stargardt disease findings, 8  
X-linked retinoschisis, 335
- OPTN*  
genetic testing, 250–252  
glaucoma mutations, 211, 215
- Optogenetics, vision restoration, 16–17
- OTUD4*, genetic modifiers, 63
- OTX2*, Leber congenital amaurosis mutations, 7
- P**
- Palmitoyl protein thioesterase (PPT), neuronal ceroid lipofuscinosis role, 103
- PAX6*  
genetic testing, 250–252  
glaucoma mutations, 209
- PCV. *See* Polyploidial choroidal vasculopathy
- PDE-β*, retinitis pigmentosa mutations, 5
- PDE6A*, retinitis pigmentosa mutations, 5
- PDE6B*, retinitis pigmentosa mutations, 5
- PDE6C*, achromatopsia mutations, 11
- PDE6H*, achromatopsia mutations, 11
- PDT. *See* Photodynamic therapy
- PDZD7*, genetic modifiers, 65
- PED. *See* Retinal pigment epithelial detachment
- PEDE. *See* Pigment epithelium-derived factor
- Pegaptanib, age-related macular degeneration management, 120

## Index

- Peripherin-2. *See* *PRPH2*
- PEX7*, Refsum disease mutation, 102
- Photocoagulation, age-related macular degeneration management, 119
- Photodynamic therapy (PDT), age-related macular degeneration management, 120–121
- PHYH*, Refsum disease mutation, 102
- Pigment epithelium-derived factor (PEDF), gene therapy
- age-related macular degeneration, 313–314
  - neuroprotection, 15
- PRPH2* diseases, 356
- PITX2*
- genetic testing, 250–252
  - glaucoma mutations, 209
- PLEKHA1*, age-related macular degeneration susceptibility studies, 129
- PLINK, single nucleotide polymorphism analysis, 45
- PLS3*, genetic modifiers, 63
- Polyploid choroidal vasculopathy (PCV), age-related macular degeneration, 116–117
- PPT. *See* Palmitoyl protein thioesterase
- Primary open-angle glaucoma. *See* Glaucoma
- Primary optic neuropathy
- genetic testing
    - approaches, 254
    - gene mutations, 252–253
    - gene therapy candidate identification, 253
    - informed genetic counseling, 253
    - limitations, 254
    - risk assessment, 253  - novel therapy identification, 254–256
  - risk factor avoidance, 253
- PRPF3, retinitis pigmentosa mutations, 35
- PRPF31, retinitis pigmentosa mutations, 30–33, 35
- PRPF4, retinitis pigmentosa mutations, 35
- PRPF6, retinitis pigmentosa mutations, 35
- PRPF8, retinitis pigmentosa mutations, 35
- PRPH2*
- animal models of mutations, 349–351
  - autosomal-dominant retinitis pigmentosa mutations, 348–349
  - central areolar choroidal dystrophy mutations, 104
  - functional overview, 347–348
  - gene therapy
    - adeno-associated virus vectors, 352–353
    - knockdown therapy, 355
    - neuroprotection, 355–356
    - plasmid DNA vectors, 353–355
    - prospects, 357
    - transgene replacement, 351–352
    - vascular endothelial growth factor inhibitors, 356–357  - genetic modifiers, 61–62
  - retinitis pigmentosa mutations, 5, 31, 33, 35
- Pseudoexfoliation syndrome. *See* Glaucoma
- ## R
- Ranibizumab, age-related macular degeneration management, 120–121
- RAP. *See* Retinal angiomatous proliferation
- RdCVF. *See* Rod-derived cone viability factor
- RDH12, retinitis pigmentosa mutations, 28
- RDS, genetic modifiers, 64
- Refsum disease
- clinical features, 102
  - hearing loss, 100
- REP1
- animal mutant studies, 279–280
  - expression and function, 278–279
  - functional overview, 10
  - gene. *See* *CHM*
- RET*, genetic modifiers, 60, 62
- Reticular pseudodrusen. *See* Drusen
- Retina, structure, 90
- Retinal angiomatous proliferation (RAP), age-related macular degeneration, 117
- Retinal pigment epithelial detachment (PED), choroidal neovascularization, 114–115
- Retinal pigment epithelium (RPE), hyperplasia, 116
- Retinitis pigmentosa (RP)
- autosomal dominant disease gene mutations. *See also* *PRPH2*; *RHO*
    - discovery, 28, 30–31
    - dominant-recessive acting mutations, 35
    - genetic testing, 28, 30–31, 36
    - overview, 27–28
    - pathogenicity, 31–32
    - prevalence of mutations, 32–35
    - protein functions, 35
    - reconciling diagnosis, family history, and molecular findings, 35–36
    - table, 29–30  - classification, 1–2
  - clinical features, 2–3, 27
  - epidemiology, 3–4, 27
  - gene therapy. *See* *PRPH2*; *RHO*
  - genetics, 4–5
  - syndromic/systemic forms, 5–7
  - treatment
    - alternative pharmacotherapy, 15–16
    - cell therapy, 17–18
    - neuroprotection, 15
    - overview, 11
    - retinal prosthetics, 16
- Retinoschisin. *See* *RS1*
- RHO*
- gene therapy
    - adeno-associated virus specificity, 389
    - clinical prospects, 395–396
    - expression levels, 389–390
    - photoreceptor rescue, 390–392



- RHO* (Continued)
    - rationale, 388–389
    - RNA replacement, 392–395
    - vectors, 389
    - zinc-finger repressors, 392
  - genomics studies, 43
  - retinitis pigmentosa mutations, 4–5, 31, 55, 387–388
  - RNA-Seq
    - age-related macular degeneration gene expression studies, 174–176
    - bioinformatics
      - alignment of data, 80
      - differential expression analysis, 80–82
      - inherited retinal disease models, 82–83
      - mechanisms, 83–84
    - next generation library preparation, 79–80
    - overview, 78–79
    - retina transcripts, 82
  - RNF216*, genetic modifiers, 63
  - Rod-derived cone viability factor (RdCVF), 15
  - ROM1*
    - genetic modifiers, 61–62, 64
    - retinitis pigmentosa mutations, 5, 33
  - RP. *See* Retinitis pigmentosa
  - RP1*, retinitis pigmentosa mutations, 5, 35
  - RP2*, retinitis pigmentosa mutations, 32, 34
  - RPE. *See* Retinal pigment epithelium
  - RPE65*
    - functional overview, 260–261
    - gene therapy
      - animal models, 415
      - clinical trials
        - outcome measures, 268
        - Phase I/II trials, 260, 263–265
        - Phase II, 265
        - Phase III, 265
        - table, 261–262
      - overview, 259–260, 427–428, 430–431
      - prevention of retina degradation, 266–267
      - prospects, 269–270
      - subretinal injection safety, 267–268
    - genetic modifiers, 68
    - retinitis pigmentosa mutations, 28
  - RPGR*
    - functional overview, 372
    - mutation effects, 105
    - retinitis pigmentosa mutations, 32–35
    - X-linked retinoschisis
      - animal models
        - dog, 373–376
        - mouse, 373
      - gene therapy
        - dog studies, 376–383
        - onset prevention, 377
        - photoreceptor rescue, 377–383
      - prospects, 383
      - vectors, 376
      - mutations and phenotypes, 371–373
      - neuroprotection studies, 376
  - RPGRIP1*
    - animal models of mutation, 365–367
    - functional overview, 364–365
    - gene therapy prospects, 367–368
    - Leber congenital amaurosis mutations, 363
  - RPGRIP1L*, genetic modifiers, 59, 64–65
  - RPIL1*, variant prioritization, 49
  - RS1*
    - developmental expression, 336
    - functional overview, 335
    - gene therapy
      - administration route, 339, 341
      - efficacy, 341–343
      - overview, 14
      - prospects, 343
      - vectors, 337–339
    - mouse mutants, 336–337, 340
    - X-linked retinoschisis mutations, 8, 335–336
- ## S
- SAA. *See* Serum Amyloid A
  - SAG, retinitis pigmentosa mutations, 5
  - SAGE. *See* Serial analysis of gene expression
  - SCA. *See* Spinocerebellar ataxia
  - Senior-Løken syndrome
    - gene mutations, 46
    - retinitis pigmentosa, 5
  - Serial analysis of gene expression (SAGE),
    - overview, 77
  - Serum Amyloid A (SAA), glaucoma
    - expression, 224
  - sFLT01, gene therapy for age-related macular degeneration, 311–312
  - SIX1*, glaucoma mutations, 211–213
  - SIX6*, glaucoma mutations, 211–213
  - SMA. *See* Spinal muscle atrophy
  - Spinal muscle atrophy (SMA), genetic modifiers, 63
  - Spinocerebellar ataxia (SCA), genetic modifiers
    - in SCA1, 62
  - Stargardt disease
    - ABCA4* mutations, 9, 42, 289
    - clinical features, 8–9
    - gene therapy. *See* *ABCA4*
  - STAT3, glaucoma expression, 224
- ## T
- TALENs, genome editing, 420–421
  - TBK1*
    - genetic testing, 250–252
    - glaucoma mutations, 211, 215

## Index

- TCF8*, genetic modifiers, 60  
TGF- $\beta$ . *See* Transforming growth factor- $\beta$   
Timolol, glaucoma management, 201  
TLRs. *See* Toll-like receptors  
TNF- $\alpha$ . *See* Tumor necrosis factor- $\alpha$   
Toll-like receptors (TLRs), glaucoma neuroinflammation role, 236–237, 240–241  
Trabeculectomy, glaucoma management, 202, 204  
Trabeculectomy, glaucoma management, 202  
Transcriptomics. *See also* RNA-Seq  
    genetic modifier identification, 62–63  
    inherited retinal degeneration, 47  
Transforming growth factor- $\beta$  (TGF- $\beta$ )  
    glaucoma expression, 222, 227, 229  
    signaling and glaucoma, 215  
Travoprost, glaucoma management, 201  
*TRPM1*, congenital stationary night blindness mutations, 10  
*TSPAN12*, linkage studies, 45  
Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )  
    glaucoma expression, 225, 228–229  
    signaling and glaucoma, 215, 241
- U**
- USH2A*, induced pluripotent stem cell modeling of mutation, 93–94  
Usher syndrome  
    gene mutations, 46  
    genetic modifiers, 65  
    hearing loss, 100–101  
    mouse models, 299–302  
    *MYO7A* gene therapy. *See* *MYO7A*  
    retinitis pigmentosa, 5–6  
    types, 100
- V**
- Valproic acid, retinal degeneration management, 15  
Vascular endothelial growth factor (VEGF)  
    inhibitor gene therapy  
        age-related macular degeneration, 310–312  
        *PRPH2* diseases, 356–357  
    inhibitor therapy for age-related macular degeneration, 120–121  
VEGF. *See* Vascular endothelial growth factor  
Vitamin A, retinal degeneration management, 11
- W**
- Whole genome sequencing  
    age-related macular degeneration susceptibility studies, 158  
    inherited retinal degeneration, 47
- X**
- X-linked retinoschisis (XLRS)  
    clinical features, 8, 333–335  
    epidemiology, 8  
    gene and cell biology, 335, 371  
    gene therapy. *See* *RPGR*; *RS1*  
    genetic modifiers, 68  
    management, 335  
    mouse models, 336–337, 340  
XLPR dog models. *See* *RPGR*  
XLRS. *See* X-linked retinoschisis
- Z**
- ZNF408*, linkage studies, 45